Thomas S. McHugh is CFO at AVADEL PHARMACEUTICALS PLC (AVDL). They have made 9 open-market trades across 1 company since 2020, most recently 2026-02-12.
CIK 0001240547
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
9 open-market purchases totalling $433K since 2020, never a sale. Across 9 scored buys the stock is up 16.8% at ninety days, and 16.0 points ahead of the S&P over the same stretch.
9 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| AVDL | 100,400 | $2.2M |
Shares reported on the most recent Form 4, priced at the 2025-03-07 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 11% | 11% | 56% |
| Avg Move | -9.8% | -18.1% | +16.8% |
| Alpha | -8.9% | -16.4% | +16.0% |
| Scored | 9 | 9 | 9 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AVDL | BUY | 2024-12-13 | 2024-12-16 | $10.44 | $24K | -3.1% | -24.9% | -18.7% |
| AVDL | BUY | 2024-12-11 | 2024-12-12 | $10.49 | $52K | -3.2% | -26.0% | -24.7% |
| AVDL | BUY | 2024-01-16 | 2024-01-16 | $14.50 | $29K | -6.9% | -4.4% | +14.5% |
| AVDL | BUY | 2023-08-14 | 2023-08-14 | $14.45 | $29K | -0.7% | -12.8% | -22.7% |
| AVDL | BUY | 2022-11-29 | 2022-11-30 | $7.80 | $39K | -13.7% | -22.6% | +7.6% |
| AVDL | BUY | 2022-05-27 | 2022-05-31 | $2.14 | $107K | +8.0% | +8.4% | +200.9% |
| AVDL | BUY | 2020-09-18 | 2020-09-21 | $6.00 | $24K | -18.2% | -19.5% | +10.9% |
| AVDL | BUY | 2020-08-28 | 2020-09-01 | $6.77 | $51K | -22.3% | -27.4% | +2.0% |
| AVDL | BUY | 2020-08-13 | 2020-08-17 | $7.78 | $78K | -28.5% | -34.1% | -18.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.